Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Summary

This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2009-03-16

Primary completion

2013-01-30

Completion

—

Drugs

Indications